• Citer

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

par Piccart-Gebhart, Martine ;Procter, Marion;Fumagalli, Debora ;de Azambuja, Evandro ;Clark, Emma;Ewer, M.;Restuccia, Eleonora;Jerusalem, Guy;Dent, Susan;Reaby, Linda;Bonnefoi, Herve;Krop, Ian;Liu, Walter Tsang-Wu;Pieńkowski, Tadeusz;Toi, Masakazu;Wilcken, Nicholas;Andersson, Michael;Im, Young Hyuck;Tseng, Ling Min;Lueck, Hans Joachim;Colleoni, Marco Angelo;Monturus, Estefania;Sicoe, Mihaela;Guillaume, Sébastien;Bines, Jose;Gelber, Richard;Viale, Giuseppe;Thomssen, Christoph
Référence Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39, 13, page (1448-1457)
Publication Publié, 2021-05

Article révisé par les pairs

• Détails
• Contenu

Titre:	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Auteur:	Piccart-Gebhart, Martine; Procter, Marion; Fumagalli, Debora; de Azambuja, Evandro; Clark, Emma; Ewer, M.; Restuccia, Eleonora; Jerusalem, Guy; Dent, Susan; Reaby, Linda; Bonnefoi, Herve; Krop, Ian; Liu, Walter Tsang-Wu; Pieńkowski, Tadeusz; Toi, Masakazu; Wilcken, Nicholas; Andersson, Michael; Im, Young Hyuck; Tseng, Ling Min; Lueck, Hans Joachim; Colleoni, Marco Angelo; Monturus, Estefania; Sicoe, Mihaela; Guillaume, Sébastien; Bines, Jose; Gelber, Richard; Viale, Giuseppe; Thomssen, Christoph
Informations sur la publication:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39, 13, page (1448-1457)
Statut de publication:	Publié, 2021-05
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:1527-7755
	info:doi/10.1200/JCO.20.01204
	info:scp/85103890335
	info:pmid/33539215